Literature DB >> 29395990

Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.

David J Birnkrant1, Katharine Bushby2, Carla M Bann3, Benjamin A Alman4, Susan D Apkon5, Angela Blackwell3, Laura E Case6, Linda Cripe7, Stasia Hadjiyannakis8, Aaron K Olson9, Daniel W Sheehan10, Julie Bolen11, David R Weber12, Leanne M Ward8.   

Abstract

A coordinated, multidisciplinary approach to care is essential for optimum management of the primary manifestations and secondary complications of Duchenne muscular dystrophy (DMD). Contemporary care has been shaped by the availability of more sensitive diagnostic techniques and the earlier use of therapeutic interventions, which have the potential to improve patients' duration and quality of life. In part 2 of this update of the DMD care considerations, we present the latest recommendations for respiratory, cardiac, bone health and osteoporosis, and orthopaedic and surgical management for boys and men with DMD. Additionally, we provide guidance on cardiac management for female carriers of a disease-causing mutation. The new care considerations acknowledge the effects of long-term glucocorticoid use on the natural history of DMD, and the need for care guidance across the lifespan as patients live longer. The management of DMD looks set to change substantially as new genetic and molecular therapies become available.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29395990      PMCID: PMC5889091          DOI: 10.1016/S1474-4422(18)30025-5

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  104 in total

1.  Effects of deflazacort vs. methylprednisone: a randomized study in kidney transplant patients.

Authors:  Jorge R Ferraris; Titania Pasqualini; Guillermo Alonso; Susana Legal; Patricia Sorroche; Ana M Galich; Héctor Jasper
Journal:  Pediatr Nephrol       Date:  2007-02-09       Impact factor: 3.714

2.  A comparison of maximal inspiratory pressure and forced vital capacity as potential criteria for initiating non-invasive ventilation in amyotrophic lateral sclerosis.

Authors:  Michelle Mendoza; Deborah F Gelinas; Dan H Moore; Robert G Miller
Journal:  Amyotroph Lateral Scler       Date:  2007-04

3.  Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.

Authors:  Davide Gatti; Franco Antoniazzi; Rosangela Prizzi; Vania Braga; Maurizio Rossini; Luciano Tatò; Ombretta Viapiana; Silvano Adami
Journal:  J Bone Miner Res       Date:  2004-12-20       Impact factor: 6.741

4.  Cardiac phenotype determines survival in Duchenne muscular dystrophy.

Authors:  David J Birnkrant; Erhan Ararat; Maroun J Mhanna
Journal:  Pediatr Pulmonol       Date:  2015-06-10

Review 5.  Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

Review 6.  Cardiac considerations in the operative management of the patient with Duchenne or Becker muscular dystrophy.

Authors:  Linda H Cripe; Joseph D Tobias
Journal:  Paediatr Anaesth       Date:  2013-07-19       Impact factor: 2.556

7.  Long term continuous positive airway pressure (CPAP) and noninvasive ventilation (NIV) in children: Initiation criteria in real life.

Authors:  A Amaddeo; J Moreau; A Frapin; S Khirani; O Felix; M Fernandez-Bolanos; A Ramirez; B Fauroux
Journal:  Pediatr Pulmonol       Date:  2016-04-25

Review 8.  Duchenne muscular dystrophy: an old anesthesia problem revisited.

Authors:  Jason Hayes; Francis Veyckemans; Bruno Bissonnette
Journal:  Paediatr Anaesth       Date:  2008-02       Impact factor: 2.556

9.  Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

Authors:  Frank Rauch; Craig F Munns; Christof Land; Moira Cheung; Francis H Glorieux
Journal:  J Bone Miner Res       Date:  2009-07       Impact factor: 6.741

10.  206th ENMC International Workshop: Care for a novel group of patients - adults with Duchenne muscular dystrophy Naarden, The Netherlands, 23-25 May 2014.

Authors:  Jes Rahbek; Birgit F Steffensen; Kate Bushby; Imelda J M de Groot
Journal:  Neuromuscul Disord       Date:  2015-05-27       Impact factor: 4.296

View more
  172 in total

1.  High prevalence of plasma lipid abnormalities in human and canine Duchenne and Becker muscular dystrophies depicts a new type of primary genetic dyslipidemia.

Authors:  Zoe White; Chady H Hakim; Marine Theret; N Nora Yang; Fabio Rossi; Dan Cox; Gordon A Francis; Volker Straub; Kathryn Selby; Constadina Panagiotopoulos; Dongsheng Duan; Pascal Bernatchez
Journal:  J Clin Lipidol       Date:  2020-05-29       Impact factor: 4.766

2.  Pulmonary and upper limbs function in children with early stage Duchenne muscular dystrophy compared to their healthy peers.

Authors:  Numan Bulut; Güllü Aydın; İpek Alemdaroğlu-Gürbüz; Ayşe Karaduman; Öznur Yılmaz
Journal:  Braz J Phys Ther       Date:  2020-06-05       Impact factor: 3.377

Review 3.  Growth, pubertal development, and skeletal health in boys with Duchenne Muscular Dystrophy.

Authors:  Leanne M Ward; David R Weber
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2019-02       Impact factor: 3.243

Review 4.  Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle.

Authors:  Giuseppe Vita; Gian Luca Vita; Olimpia Musumeci; Carmelo Rodolico; Sonia Messina
Journal:  Neurol Sci       Date:  2019-02-25       Impact factor: 3.307

Review 5.  Bone Health and Osteoporosis Management of the Patient With Duchenne Muscular Dystrophy.

Authors:  Leanne M Ward; Stasia Hadjiyannakis; Hugh J McMillan; Garey Noritz; David R Weber
Journal:  Pediatrics       Date:  2018-10       Impact factor: 7.124

6.  Evaluating Implementation of the Updated Care Considerations for Duchenne Muscular Dystrophy.

Authors:  Katherine S Ong; Kathi Kinnett; Rieza Soelaeman; Lauren Webb; Jennifer S Bain; Ann S Martin; Christina Westfield; Julie Bolen; Natalie Street
Journal:  Pediatrics       Date:  2018-10       Impact factor: 7.124

7.  Obesity and Endocrine Management of the Patient With Duchenne Muscular Dystrophy.

Authors:  David R Weber; Stasia Hadjiyannakis; Hugh J McMillan; Garey Noritz; Leanne M Ward
Journal:  Pediatrics       Date:  2018-10       Impact factor: 7.124

8.  Bone Health and Endocrine Care of Boys with Duchenne Muscular Dystrophy: Data from the MD STARnet.

Authors:  David R Weber; Shiny Thomas; Stephen W Erickson; Deborah Fox; Joyce Oleszek; Shree Pandya; Yedatore Venkatesh; Christina Westfield; Emma Ciafaloni
Journal:  J Neuromuscul Dis       Date:  2018

9.  Variations in native T1 values in patients with Duchenne muscular dystrophy with and without late gadolinium enhancement.

Authors:  Sean M Lang; Tarek Alsaied; Philip R Khoury; Thomas D Ryan; Michael D Taylor
Journal:  Int J Cardiovasc Imaging       Date:  2020-09-20       Impact factor: 2.357

10.  Peak Cough Flow in Children with Neuromuscular Disorders.

Authors:  Nidhi Kotwal; Prateek J Shukla; Geovanny F Perez
Journal:  Lung       Date:  2020-02-24       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.